trending Market Intelligence /marketintelligence/en/news-insights/trending/gu9d60logwldv74dfwjxxa2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

NICE rejects Roche's breast cancer drug on financial grounds

Street Talk Episode 41 - How to Win the Funding Battle, Use Fintech to Play Offense

Forward Spark Spreads Suggest Rising Profitability Of US Renewables As Sector Matures

MA Activity The Big Story In Mature Online Video Platform Market

Martina Cheung Backs The Quality Program


NICE rejects Roche's breast cancer drug on financial grounds

The U.K.'s National Institute for Health and Care Excellence rejected Roche Holding Ltd.'s breast cancer drug Kadcyla on financial grounds.

The government body, which evaluates drugs for use in the National Health Service, said the cost of the £90,000 per year drug did not justify its benefits despite a discount from the company.

NICE's decision is preliminary, however, and the government body is open to consultation.

Around 1,200 people with HER2-positive, unresectable, metastatic breast cancer would be eligible to receive Kadcyla if it were to be recommended.

Patients on Roche's Kadcyla are understood to live up to 9 months longer when compared to those taking the alternative, lapatinib plus capecitabine.